RAPP

Rapport Therapeutics

18.46 USD
+0.43
2.38%
At close Dec 24, 4:00 PM EST
1 day
2.38%
5 days
-2.84%
1 month
-17.33%
3 months
-13.70%
6 months
-17.22%
Year to date
-11.25%
1 year
-11.25%
5 years
-11.25%
10 years
-11.25%
 

About: Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.

0
Funds holding %
of 6,809 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

173% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 11

57% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 7

54% more funds holding

Funds holding: 35 [Q2] → 54 (+19) [Q3]

3.1% more ownership

Funds ownership: 74.47% [Q2] → 77.57% (+3.1%) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 4 [Q2] → 4 (+0) [Q3]

2% less capital invested

Capital invested by funds: $593M [Q2] → $580M (-$13M) [Q3]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$42
128%
upside
Avg. target
$42
128%
upside
High target
$42
128%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
Jones Trading
Justin Walsh
18% 1-year accuracy
2 / 11 met price target
128%upside
$42
Buy
Initiated
18 Oct 2024

Financial journalist opinion

Neutral
GlobeNewsWire
2 weeks ago
Rapport Therapeutics Presents Data Demonstrating Consistent Association Between Decreases in RNS Measured Long Episodes and Meaningful Reductions in Clinical Seizures
A 30% reduction in long episodes was shown to be associated with a 50% or greater reduction in clinical seizures in a post-hoc analysis, validating the biomarker for proof-of-concept studies Change in long episode frequency is the primary endpoint for Rapport's ongoing Phase 2a proof-of-concept trial in focal epilepsy, with topline data expected in mid-2025 Data from additional studies, including preclinical seizure data and Phase 1 pharmacokinetic and safety trial results, support the potential of RAP-219 as a transformational treatment for patients with focal epilepsy BOSTON and LOS ANGELES, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients suffering from central nervous system (CNS) disorders, presents novel findings on the association between a seizure biomarker used in the Company's proof-of-concept trial for RAP-219 and clinical seizures. The analysis demonstrated a linear relationship between changes in long episode (LE) frequency and clinical seizure frequency and identified the benchmark to predict clinically meaningful seizure reduction.
Rapport Therapeutics Presents Data Demonstrating Consistent Association Between Decreases in RNS Measured Long Episodes and Meaningful Reductions in Clinical Seizures
Neutral
GlobeNewsWire
1 month ago
Rapport Therapeutics to Present Data at American Epilepsy Society Annual Meeting
Poster presentations on Phase 2a trial seizure biomarker, preclinical, and Phase 1 clinical data Poster presentations on Phase 2a trial seizure biomarker, preclinical, and Phase 1 clinical data
Rapport Therapeutics to Present Data at American Epilepsy Society Annual Meeting
Neutral
GlobeNewsWire
1 month ago
Rapport Therapeutics to Present at Stifel Healthcare Conference and Jefferies London Healthcare Conference in November
BOSTON and SAN DIEGO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of small molecule precision medicines for patients suffering from central nervous system (CNS) disorders, today announced that management will participate in fireside chats at two upcoming investor conferences as follows:
Rapport Therapeutics to Present at Stifel Healthcare Conference and Jefferies London Healthcare Conference in November
Positive
Benzinga
2 months ago
This Rapport Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
This Rapport Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Neutral
GlobeNewsWire
3 months ago
Rapport semestriel Pilier 3 - 30 juin 2024
Veuillez trouver ci-joint le rapport annuel Pilier 3 au 30 juin 2024 Attachment Rapport semestriel Pilier 3 - 30 juin 2024
Rapport semestriel Pilier 3 - 30 juin 2024
Neutral
GlobeNewsWire
3 months ago
Rapport Therapeutics to Present at Upcoming Epilepsy Medical Conferences
BOSTON and SAN DIEGO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders, today announced presentations at two upcoming medical conferences: the International League Against Epilepsy (ILAE) 15th Annual European Epilepsy Congress (EEC) in Rome, Italy, September 7-11, 2024, and the 2024 Epilepsy Foundation Pipeline Conference in Atlanta, Ga., September 25-26, 2024.
Rapport Therapeutics to Present at Upcoming Epilepsy Medical Conferences
Neutral
GlobeNewsWire
3 months ago
Rapport Therapeutics to Present at 22nd Annual Morgan Stanley Global Healthcare Conference and TD Cowen's 4th Annual Novel Mechanisms in Neuropsychiatry Summit
BOSTON and SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders, today announced that management will present at two upcoming investor conferences:
Rapport Therapeutics to Present at 22nd Annual Morgan Stanley Global Healthcare Conference and TD Cowen's 4th Annual Novel Mechanisms in Neuropsychiatry Summit
Positive
InvestorPlace
4 months ago
The 3 Best Healthcare Stocks to Buy in August 2024
The healthcare industry has been a critical part of the economy for a long time. According to a McKinsey & Company report, the healthcare industry is expected to grow at 7% from 2022 to 2027.
The 3 Best Healthcare Stocks to Buy in August 2024
Neutral
InvestorPlace
4 months ago
3 Under-The-Radar Healthcare Stocks to Buy for Outsized Returns
Global markets are down as fears of an economic downturn triggered a near-term crisis. This is a reminder that corrections can come from most unexpected events.
3 Under-The-Radar Healthcare Stocks to Buy for Outsized Returns
Neutral
GlobeNewsWire
4 months ago
Rapport Therapeutics to Present Data for TARPγ8 AMPAR Negative Modulator at IASP 2024 World Congress on Pain
Preclinical data on TARPγ8 targeted compound, an analog to Rapport's lead product candidate RAP-219, demonstrated analgesic activity in multiple pain models Preclinical data on TARPγ8 targeted compound, an analog to Rapport's lead product candidate RAP-219, demonstrated analgesic activity in multiple pain models
Rapport Therapeutics to Present Data for TARPγ8 AMPAR Negative Modulator at IASP 2024 World Congress on Pain
Charts implemented using Lightweight Charts™